Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PR9I
|
|||
| Former ID |
DNC000870
|
|||
| Drug Name |
Lerdelimumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2], [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007 Oct;114(10):1822-30. | |||
| REF 2 | TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2301-8. | |||
| REF 3 | Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3394-401. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.